SCIE收录的胃肠肝病学期刊发表的中国内地作者的肝脏疾病研究文献计量分析

赵天业; 吴燕华; 潘禹辰; 易嘉欣; 吕海永; 牛俊奇; 姜晶

doi:10.3969/j.issn.1001-5256.2022.04.024

SCIE收录的胃肠肝病学期刊发表的中国内地作者的肝脏疾病研究文献计量分析

DOI: 10.3969/j.issn.1001-5256.2022.04.024

a.
吉林大学第一医院临床研究部，长春 130021
b.
吉林大学第一医院感染病与病原生物学中心肝胆胰内科，长春 130021

基金项目:

吉林省科技发展计划项目 (20200403098SF);

吉林大学第一医院青年发展基金项目 (JDYY11202124)

利益冲突声明：本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。

作者贡献声明：赵天业、易嘉欣、吕海永参与了研究数据的获取分析解释过程；牛俊奇、姜晶对研究的思路和设计有关键贡献；吴燕华、潘禹辰参与起草与修改文章关键内容。

详细信息

通信作者:
姜晶，jiangjing19702000@jlu.edu.cn

计量
- 文章访问数: 669
- HTML全文浏览量: 168
- PDF下载量: 71
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-05
- 出版日期: 2022-04-20

A bibliometric analysis of liver disease research articles published by Chinese mainland authors in Gastroenterology & Hepatology journals indexed in Science Citation Index Expanded

a.
Division of Clinical Research, The First Hospital of Jilin University, Changchun 130021, China
b.
Department of Hepatology, Center of Infections Diseases and Pathogenic Biology, The First Hospital of Jilin University, Changchun 130021, China

Research funding:

Jilin Province Science and Technology Development Program (20200403098SF);

The Youth Fund of the First Hospital of Jilin University (JDYY11202124)

More Information

Corresponding author: JIANG Jing, jiangjing19702000@jlu.edu.cn(ORCID: 0000-0001-9714-9255)

摘要

摘要: 目的检索2016年—2020年中国(不含港澳台地区)作者在SCIE(Science Citation Index Expanded)数据库收录的胃肠肝病学期刊上发表的肝脏疾病相关论文，对其题录与引文数据进行统计分析，以了解中国学者在肝脏疾病研究领域的贡献及其影响力。方法文献计量学分析数据来源于SCIE数据库与JCR(Journal Citation Report)。在SCIE数据库中检索出版年为2016年—2020年发表在JCR胃肠肝病学期刊上，题名或摘要中包含Liver、Hepatocellular、Hepatitis、Cirrhosis或Hepatic，出版物类型为Article的期刊文章，排除临床指南，并筛选通信作者单位含有中国(不含港澳台地区)机构的记录。使用R package bibliometrix计算纳入文献在2016年—2020年被中国作者和全球作者在胃肠肝病学期刊发表的肝脏疾病研究引用的频次。使用R package DescTools对构成比的变化进行Cochran-Armitage趋势检验。结果 2016年—2020年Q1区胃肠肝病学期刊上，中国作者发表的肝脏疾病研究占比为9.5%。近年，中国作者在高水平胃肠肝病学期刊(Q1区)上发表的肝脏疾病研究数量不断增加，占全球研究的比例从6.0%不断上升至12.2%(P＜0.001)。中国作者在Q1区胃肠肝病学期刊发表的肝脏疾病研究获国自然基金资助的比例达79.7%，5年间，各分区胃肠肝病学期刊上发表的中国作者的研究获国自然基金资助的比例均无明显变化。比较被中国与全球作者在胃肠肝病学期刊上发表的肝脏疾病研究引用频次，显示了中国作者发表的在国内和国际学界均具有较高影响的肝脏疾病研究。结论近年，中国作者在SCIE收录、高影响力的胃肠肝病学期刊发表的肝脏疾病研究数量不断增加，其中大部分研究获国自然基金资助。中国学者在胃肠肝病学期刊上发表的肝脏疾病论文被国内学界和国际学界广泛认可。
- 肝疾病 /
- 文献计量学 /
- 胃肠病学 /
- 数据库, 文献型 /
- 医学书目
Abstract: Objective To investigate the articles on liver diseases published by authors from China (excluding Hong Kong, Macao, and Taiwan regions) in Gastroenterology & Hepatology journals indexed in Science Citation Index Expanded (SCIE) in 2016-2020, to analyze the bibliographic and citation data of these articles, and to understand the contribution and impact of Chinese scholars in the field of liver disease research in recent years. Methods The data for bibliometric analysis came from the SCIE database and Journal Citation Reports (JCR). The SCIE database was searched for the journal articles published in JCR Gastroenterology & Hepatology journals in 2016-2020, with a title or abstract containing "Liver", "Hepatocellular", "Hepatitis", "Cirrhosis", or "Hepatic" and a publication type of Article. Clinical guidelines were excluded, and the records with the corresponding author's affiliation containing institutions in China (excluding Hong Kong, Macao, and Taiwan regions) were screened out. R package bibliometrix was used to calculate the frequency of citations of included articles by liver disease studies published by Chinese and global authors in the Gastroenterology & Hepatology journals in 2016-2020, and R package DescTools was used to perform the Cochran-Armitage trend test to observe the change in composition ratio. Results In the Q1 Gastroenterology & Hepatology journals in 2016-2020, liver disease studies published by Chinese authors accounted for 9.5%. In recent years, the proportion of liver disease studies published by Chinese authors in Q1 Gastroenterology & Hepatology journals continues to increase from 6.0% to 12.2% (P < 0.001). Among the liver disease studies published by Chinese authors in Q1 Gastroenterology & Hepatology journals, 79.7% were funded by National Natural Science Foundation of China, and there was no significant change in the proportion of studies funded by National Natural Science Foundation of China and published by Chinese authors in each partition of Gastroenterology & Hepatology journals in 2016-2020. The frequency of citations of included articles by liver disease studies published by Chinese and global authors in the Gastroenterology & Hepatology journals showed that liver disease studies published by Chinese authors had a high impact in both domestic and international academic communities. Conclusion In recent years, there has been a constant increase in the number of liver disease studies published by Chinese authors in high-impact Gastroenterology & Hepatology journals indexed in SCIE, and most of these studies have been funded by National Natural Science Foundation of China. The liver disease studies published by Chinese authors in Gastroenterology & Hepatology journals have been widely recognized by domestic and international academic communities.
- Liver Diseases /
- Bibliometrics /
- Gastroenterology /
- Databases, Bibliographic /
- Bibliography of Medicine

HTML全文

图 1 2016年—2020年中国作者在Q1区胃肠肝病学期刊发表肝脏疾病研究被引频次分布

注：TC，总被引频次；LC，被中国作者在胃肠肝病学期刊上发表的肝脏疾病研究引用频次；GC, 被全球作者在胃肠肝病学期刊上发表的肝脏疾病研究引用频次；图中省略了被引频次＞50的点。

Figure 1. The distribution of citation frequency of Chinese authors' published liver diseases research in Q1 Gastroenterology and Hepatology journals during 2016 to 2020

下载: 全尺寸图片幻灯片

表 1 2016年—2020年在SCIE收录的胃肠肝病学期刊上发表的肝脏疾病研究特征

Table 1. Characteristics of liver diseases research published on Gastroenterology & Hepatology journals indexed in SCIE during 2016 to 2020

项目	中国作者发文数量(篇)	全球作者发文数量(篇)	中国作者发文占比(%)
出版年
2016	446	3294	13.5
2017	464	3324	14.0
2018	474	3259	14.5
2019	640	3618	17.7
2020	681	3596	18.9
期刊JCR分区
Q1	473	4961	9.5
Q2	984	5666	17.4
Q3	799	3413	23.4
Q4	449	3051	14.7
开放获取	1283	8630	14.9
被引频次
0	302	1447	20.9
1~5	1066	5840	18.3
6~10	514	3187	16.1
11~20	464	3142	14.8
＞20	359	3485	10.3

下载: 导出CSV

表 2 2016年—2020年中国作者在2020年Q1区胃肠肝病学期刊发表肝脏疾病研究情况

Table 2. Chinese authors published liver diseases research on Gastroenterology & Hepatology journals in the Q1 of 2020 during 2016-2020

序号	期刊	中国作者发文数量(篇)	全球作者发文数量(篇)	中国作者发文占比(%)
1	Hepatology	226	1382	16.4
2	Journal of Hepatology	97	918	10.6
3	Alimentary Pharmacology & Therapeutics	21	390	5.4
4	Gastroenterology	20	365	5.5
5	Clinical Gastroenterology and Hepatology	11	296	3.7
6	Gut	38	270	14.1
7	Clinics in Liver Disease	0	215	0
8	Journal of Gastroenterology	5	183	2.7
9	American Journal of Gastroenterology	8	178	4.5
10	Journal of Hepato-Biliary-Pancreatic Sciences	6	151	4.0
11	Liver Cancer	8	121	6.6
12	Clinical and Molecular Hepatology	3	100	3.0
13	Lancet Gastroenterology & Hepatology	6	89	6.7
14	Hepatobiliary Surgery and Nutrition	8	75	10.7
15	Cellular and Molecular Gastroenterology and Hepatology	4	60	6.7
16	Gastrointestinal Endoscopy	0	48	0
17	Gut Microbes	5	32	15.6
18	Gastric Cancer	5	31	16.1
19	Endoscopy	1	24	4.2
20	Digestive Endoscopy	0	19	0
21	Journal of Crohn’s & Colitis	1	9	11.1
22	Nature Reviews Gastroenterology & Hepatology	0	5	0
23	Seminars in Liver Disease	0	0	-

下载: 导出CSV

表 3 2016年—2020年中国作者在SCIE收录的不同分区胃肠肝病学期刊上发表的肝脏疾病研究占全球同分区胃肠肝病学期刊上发表的肝脏疾病研究比例变化

Table 3. The proportion of liver disease research published by Chinese authors in different divisions of Gastroenterology & Hepatology journals indexed in SCIE accounted for the change in the proportion of liver diseases research published in the same division in the world during 2016 to 2020

项目	2016年	2017年	2018年	2019年	2020年	Z值	P值
Q1区(中国/全球)	6.0%(58/961)	8.0%(77/961)	9.6%(95/987)	11.5%(121/1052)	12.2%(122/1000)	-0.05	＜0.001¹⁾
Q2区(中国/全球)	16.7%(193/1154)	17.6%(196/1112)	14.3%(153/1069)	19.2%(232/1210)	18.7%(210/1121)	-1.59	0.056
Q3区(中国/全球)	19.9%(111/559)	22.5%(137/610)	23.6%(148/626)	25.6%(195/761)	24.3%(208/857)	-2.20	0.014¹⁾
Q4区(中国/全球)	13.5%(84/620)	8.4%(54/641)	13.5%(78/577)	15.5%(92/595)	22.8%(141/618)	-5.72	＜0.001¹⁾
注：1)P＜0.025。

下载: 导出CSV

表 4 2016年—2020年中国作者在SCIE收录的胃肠肝病学期刊上发表的肝脏疾病研究获国家自然科学基金资助情况

Table 4. The research on liver diseases published by Chinese authors in the Gastroenterology & Hepatology journals indexed in SCIE was funded by the National Natural Science Foundation of China during 2016 to 2020

项目	2016年	2017年	2018年	2019年	2020年	Z值	P值
Q1区(资助/全部)	81.0%(47/58)	76.6%(59/77)	91.6%(87/95)	80.2%(97/121)	71.3%(87/122)	1.62	0.052¹⁾
Q2区(资助/全部)	46.1%(89/193)	49.5%(97/196)	53.6%(82/153)	52.6%(122/232)	53.8%(113/210)	-1.65	0.049¹⁾
Q3区(资助/全部)	52.3%(58/111)	39.4%(54/137)	49.3%(73/148)	49.2%(96/195)	40.9%(85/208)	1.00	0.159
Q4区(资助/全部)	35.7%(30/84)	46.3%(25/54)	32.1%(25/78)	35.9%(33/92)	38.3%(54/141)	0.04	0.486¹⁾
注：1)为对下降趋势进行的检验。

下载: 导出CSV

表 5 2016年—2020年中国作者在SCIE收录的胃肠肝病学期刊上发表的肝脏疾病研究被中国作者与全球作者在胃肠肝病学期刊上发表的肝脏疾病研究引用频次排名前9的研究

Table 5. The liver disease research published by Chinese authors in the Gastroenterology & Hepatology journals indexed in SCIE was the 9 most frequently cited studies of liver disease research published by Chinese authors and global authors in the Gastroenterology & Hepatology journals during 2016 to 2020

题名	期刊	出版年	通信作者单位	TC(排名)	GC(排名)	LC(排名)
Development of Diagnostic Criteria and A Prognostic Score for Hepatitis B Virus-Related Acute- On-Chronic Liver Failure	GUT	2018	浙江大学医学院附属第一医院	74(54)	20(6)	20(1)
Serum Hepatitis B Virus RNA is Encapsidated Pregenome RNA that may be Associated with Persistence of Viral Infection and Rebound	J HEPATOL	2016	北京大学	191(13)	45(1)	19(2)
New Classification of Liver Biopsy Assessment for Fibrosis in Chronic Hepatitis B Patients Before and After Treatment	HEPATOLOGY	2017	首都医科大学附属北京友谊医院	59(76)	18(7)	13(3)
Covered Tips Versus Endoscopic Band Ligation Plus Propranolol for The Prevention of Variceal Rebleeding in Cirrhotic Patients with Portal Vein Thrombosis: A Randomised Controlled Trial	GUT	2018	空军军医大学西京医院	50(103)	16(9)	11(4)
Targeting Hepatic Traf1-Ask1 Signaling to Improve Inflammation, Insulin Resistance, And Hepatic Steatosis	J HEPATOL	2016	武汉大学	73(58)	14(12)	11(4)
Liver Transplantation for Hepatocellular Carcinoma Beyond the Milan Criteria	GUT	2016	浙江大学医学院附属第一医院	95(40)	21(5)	10(6)
Targeting Traf3 Signaling Protects Against Hepatic Ischemia/Reperfusions Injury	J HEPATOL	2016	武汉大学	59(76)	10(21)	10(6)
Perioperative Blood Transfusion Does Not Influence Recurrence-Free and Overall Survivals After Curative Resection for Hepatocellular Carcinoma A Propensity Score Matching Analysis	J HEPATOL	2016	海军军医大学附属东方肝胆外科医院	69(60)	13(15)	9(8)
Circular RNA Circmto1 Acts as The Sponge of Microrna-9 To Suppress Hepatocellular Carcinoma Progression	HEPATOLOGY	2017	浙江大学，海军军医大学	664(1)	10(22)	9(8)
Eight Millimetre Covered Tips Does Not Compromise Shunt Function but Reduces Hepatic Encephalopathy in Preventing Variceal Rebleeding	J HEPATOL	2017	空军军医大学西京医院	56(86)	22(4)	8(10)
……	……	……	……	……	……	……
Comparison of Laboratory Tests, Ultrasound, or Magnetic Resonance Elastography to Detect Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis	HEPATOLOGY	2017	华中科技大学同济医学院附属协和医院	238(9)	45(1)	7(12)
……	……	……	……	……	……	……
COVID-19: Abnormal Liver Function Tests	J HEPATOL	2020	南方科技大学第二附属医院	242(8)	26(3)	5(22)
Clinical Features of COVID-19-Related Liver Functional Abnormality	CLIN GASTROENTEROL HEPATOL	2020	复旦大学附属公共卫生临床中心	236(10)	17(8)	5(23)
注：J HEPATOL，Journal of Hepatology；CLIN GASTROENTEROL HEPATOL，Clinical Gastroenterology and Hepatology。

下载: 导出CSV

参考文献(24)

[1]	MAYO CLINIC STAFF. Liver disease[OL]. (2020-2-21)[2021-7-31]. https://www.mayoclinic.org/diseases-conditions/liver-problems/symptoms-causes/syc-20374502.
[2]	European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
[3]	ELLEGAARD O, WALLIN JA. The bibliometric analysis of scholarly production: How great is the impact?[J]. Scientometrics, 2015, 105(3): 1809-1831. DOI: 10.1007/s11192-015-1645-z.
[4]	YANG HY, WANG D, CHEN C, et al. Global research status of gastroenterology and hepatology: A bibliometrics study[J]. Medicine (Baltimore), 2021, 100(15): e25291. DOI: 10.1097/MD.0000000000025291.
[5]	HU SK, HUANG J, HONG WD, et al. The 50 most-cited articles in gastroenterology and hepatology from Mainland China[J]. Pak J Med Sci, 2017, 33(1): 215-220. DOI: 10.12669/pjms.331.12286.
[6]	MA HY, AO YK, LIU WB, et al. A bibliometric analysis on cohort study of liver cancer in China[J]. Chin J Epidemiol, 2020, 41(1): 115-119. DOI: 10.3760/cma.j.issn.0254-6450.2020.01.021. 马宏宇, 敖杨坤, 刘文斌, 等. 中国肝癌相关队列研究的文献计量分析[J]. 中华流行病学杂志, 2020, 41(1): 115-119. DOI: 10.3760/cma.j.issn.0254-6450.2020.01.021.
[7]	LI G, LIN J, JIANG C, et al. Trends in chronic hepatitis B treatment-related research from 1973 to 2018: A bibliometric and visual analysis[J]. J Int Med Res, 2020, 48(4): 300060519893234. DOI: 10.1177/0300060519893234.
[8]	XU G, JIN B, XIAN X, et al. Evolutions in the management of hepatocellular carcinoma over last 4 decades: An analysis from the 100 most influential articles in the field[J]. Liver Cancer, 2021, 10(2): 137-150. DOI: 10.1159/000513412.
[9]	HU AGZ. Public funding and the ascent of Chinese science: Evidence from the National Natural Science Foundation of China[J]. Research Policy, 2020, 49(5): 13. DOI: 10.1016/j.respol.2020.103983.
[10]	LIU Y, GAO Z, WANG H, et al. Analysis of projects funded by the National Natural Science Foundation of China during the years of 2014-2018[J]. Ann Transl Med, 2019, 7(12): 267. DOI: 10.21037/atm.2019.05.63.
[11]	R CORE TEAM. R: A language and environment for statistical computing[OL]. https://www.R-project.org/.
[12]	ARIA M, CUCCURULLO C. bibliometrix: An R-tool for comprehensive science mapping analysis[J]. J Informetr, 2017, 11(4): 959-975. DOI: 10.1016/j.joi.2017.08.007.
[13]	SIGNORELL A. DescTools: Tools for descriptive statistics[OL]. https://cran.r-project.org/package=DescTools.
[14]	NESHAT SY, QUIROZ VM, WANG Y, et al. Liver disease: Induction, progression, immunological mechanisms, and therapeutic interventions[J]. Int J Mol Sci, 2021, 22(13): 6777. DOI: 10.3390/ijms22136777.
[15]	IOANNOU GN, GREEN PK, BERRY K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma[J]. J Hepatol, 2018, 68(1): 25-32. DOI: 10.1016/j.jhep.2017.08.030.
[16]	EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
[17]	BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66. DOI: 10.1016/S0140-6736(16)32453-9.
[18]	LOOMBA R, ADAMS LA. Advances in non-invasive assessment of hepatic fibrosis[J]. Gut, 2020, 69(7): 1343-1352. DOI: 10.1136/gutjnl-2018-317593.
[19]	RUDIGER MS, ANTONS D, SALGE TO. The explanatory power of citations: A new approach to unpacking impact in science[J]. Scientometrics, 2021, 126: 9779-9809. DOI: 10.1007/s11192-021-04103-w.
[20]	ZHU HR. Home country bias in academic publishing: A case study of the New England Journal of Medicine[J]. Learned Publishing, 2021, 34(4): 578-584. DOI: 10.1002/leap.1404.
[21]	WANG J, SHEN T, HUANG X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016, 65(4): 700-710. DOI: 10.1016/j.jhep.2016.05.029.
[22]	XU X, LU D, LING Q, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J]. Gut, 2016, 65(6): 1035-1041. DOI: 10.1136/gutjnl-2014-308513.
[23]	SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65(5): 1438-1450. DOI: 10.1002/hep.29009.
[24]	LV Y, QI X, HE C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: A randomised controlled trial[J]. Gut, 2018, 67(12): 2156-2168. DOI: 10.1136/gutjnl-2017-314634.